Therapy Area
An NRTI for treatment of hepatitis B (HBV) and HIV patients.
Competitive Edge
Against both multiresistant HBV and HIV that has become multiresistant to other drugs on the market. Very potent effect in hepatitis model in vivo. Excellent pharmacokinetic properties in phase I and effect against multiresistant HIV in pilot study.
Licensee Hainan Noken has licensed MIV-210 for the Chinese market and is developing MIV-210 as a potential treatment against hepatitis B.
